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Ectonucleotide pyrophosphatase/phosphodiester-
ase-1 (NPP1) converts extracellular nucleotides into
inorganic pyrophosphate, whereas its close rela-
tive NPP2/autotaxin hydrolyzes lysophospholipids.
NPP1 regulates calcification in mineralization-
competent tissues, and a lack of NPP1 function un-
derlies calcification disorders. Here, we show that
NPP1 forms homodimers via intramembrane disul-
fide bonding, but is also processed intracellularly
to a secreted monomer. The structure of secreted
NPP1 reveals a characteristic bimetallic active site
and a nucleotide-binding groove, but it lacks the
lipid-binding pocket and open tunnel present in
NPP2. A loop adjacent to the nucleotide-binding
site, which is disordered in NPP2, is well ordered in
NPP1 and might promote nucleotide binding. Re-
markably, the N-terminal somatomedin B-like
domains of NPP1, unlike those in NPP2, are flexible
and do not contact the catalytic domain. Our results
provide a structural basis for the nucleotide pyro-
phosphatase activity of NPP1 and help to under-
stand how disease-causing mutations may affect
NPP1 structure and function.
INTRODUCTION
Ectonucleotide pyrophosphatase/phosphodiesterase-1 (NPP1
or ENPP1), formerly known as plasma cell membrane glycopro-
tein 1 (PC-1), is the founding member of the NPP family, consist-
ing of seven isozymes with a structurally related catalytic
domain. The NPPs hydrolyze phosphodiester or pyrophosphate
bonds in various substrates, including nucleoside triphosphates,
lysophospholipids, and choline phosphate esters (Bollen et al.,
2000; Stefan et al., 2005; Zimmermann et al., 2012). NPP1 and1948 Structure 20, 1948–1959, November 7, 2012 ª2012 Elsevier LtdNPP2, also known as autotaxin (ATX), are the best-characterized
NPP family members. NPP1 is a glycoprotein that forms
disulfide-bonded homodimers in the plasma membrane and
mineral-depositing matrix vesicles of osteoblasts and chondro-
cytes (Johnson et al., 1999, 2001; Terkeltaub, 2006; Vaingankar
et al., 2004). NPP1 hydrolyzes extracellular nucleotides into
inorganic pyrophosphate (PPi), a potent inhibitor of hydroxyapa-
tite (HA) crystal formation in mineralization-competent tissues
(Terkeltaub, 2001). NPP2/ATX is a secreted lysophospholipase
D that converts lysophosphatidylcholine into the lipid mediator
lysophosphatidic acid (LPA) (Umezu-Goto et al., 2002; Toku-
mura et al., 2002; van Meeteren and Moolenaar, 2007). NPP2
can also hydrolyze nucleotides, albeit with much lower efficiency
than NPP1 (Gijsbers et al., 2003a, 2003b).
By generating PPi, NPP1 is a key regulator of tissue calcifica-
tion and bone development. PPi inhibits mineralization by bind-
ing to nascent HA crystals, thereby preventing further growth
of these crystals (Addison et al., 2007; Terkeltaub, 2006). On
the other hand, PPi is hydrolyzed by tissue-nonspecific alkaline
phosphatase (TNAP) into inorganic phosphate (Pi), which co-
crystallizes with calcium into HA and thereby promotes bone
formation (Ciancaglini et al., 2010; Harmey et al., 2004; Hessle
et al., 2002; Johnson et al., 2000). Thus, PPi has a dual role in
that it can both suppress and promote HA crystal deposition,
depending on the relative expression levels and catalytic activi-
ties of NPP1 and TNAP. A distorted balance of Pi/PPi ultimately
leads to pathological calcification, as occurs in aging, osteoar-
thritis, and other diseases.
Our current understanding of NPP1’s role in physiological and
pathological mineralization is largely derived from studies on
NPP1-deficient mice and patients with ENPP1mutations result-
ing in calcification disorders. NPP1-deficient mice show reduced
levels of extracellular PPi, causing pathological calcification of
cartilage and soft tissues, such as ligaments, tendons, and
arterial smooth muscle walls (Hessle et al., 2002; Johnson
et al., 2003, 2005; Okawa et al., 1998), as well as abnormal
bone development (Mackenzie et al., 2012). In humans, homozy-
gous loss-of-function mutations in ENPP1 are associated with
general arterial calcification of infancy (GACI), a life-threateningAll rights reserved
Figure 1. Monomeric, Soluble NPP1 Is Generated by the Intracellular
Cleavage of the N Terminus
(A) Domain structure of NPP1. PDE, phosphodiesterase catalytic domain.
(B) HEK293T cells were transiently transfected with HA-NPP1-Myc. Immu-
noblotting of the lysates was performed under nonreducing conditions. Note
that the smallest monomeric band could be visualized with anti-Myc anti-
bodies, but not with anti-HA antibodies.
(C) NPP1-S74A is mainly present in cell lysates as a cleaved monomer (upper
panel) and is largely recovered in the culture medium (lower panel).
(D) EYFP-NPP1-ECFP fusions with NPP1-WT and NPP1-S74A were tran-
siently expressed in HEK293T cells, and their subcellular distribution was
analyzed by confocal microscopy. The NPP1-WT fusion is mainly expressed
as an uncleaved protein that is associated with the Golgi and plasma
membrane (merged yellow color). However, a fraction of the NPP1-WT fusion
is N-terminally cleaved and is cytoplasmic (red color). The NPP1-S74A fusion
is much more abundant in the cytoplasm.
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Structure of NPP1disease of early childhood (Nitschke et al., 2012; Ruf et al., 2005;
Rutsch et al., 2003, 2008), and with hypophosphatemic rickets
(Levy-Litan et al., 2010; Lorenz-Depiereux et al., 2010; Saito
et al., 2011). Furthermore, reduced NPP1 expression correlates
with calcification in atherosclerotic plaques and with risk factors
of atherosclerosis (Nitschke et al., 2011).
Conversely, upregulated NPP1 expression can lead to patho-
logical calcification in cartilage due to the formation of calcium
pyrophosphate dihydrate (CPPD) crystals. Increased NPP1
expression, as found in chondrocytes of aging persons, is
characterized by the accumulation of CPPD crystals in joints,
a disorder known as chondrocalcinosis (Sun et al., 2010; Zhang
et al., 2007). In addition, excess PPi promotes apoptosis of
chondrocytes and may thereby contribute to the pathogenesis
of osteoarthritis (Johnson et al., 2001; Sun et al., 2010). Elevated
NPP1 expression can also induce apoptosis-mediated calcifi-
cation of the aortic valves (Coˆte´ et al., 2012). In mice, NPP1 defi-
ciency restores the hypomineralization phenotype of TNAP
knockouts (Anderson et al., 2005; Hessle et al., 2002). Collec-
tively, these findings suggest that local inhibition of NPP1 activity
is a valuable strategy for treating calcification disorders such as
chondrocalcinosis and hypophosphatasia, a mineralization
disorder caused by TNAP deficiency (Hessle et al., 2002; Whyte,
2010). A few NPP1 inhibitors have been identified to date, but
they lack selectivity among other NPPs and ecto-nucleotidases
(Eliahu et al., 2010; Le´vesque et al., 2007).
The domain structure of NPP1 is similar but not identical to that
of NPP2. In both enzymes, which share about 45% sequence
identity, the central catalytic domain (PDE) is C-terminally
flanked by a nuclease-like (NUC) domain and N terminally by
two somatomedin B-like (SMB) domains (Figure 1A). The crystal
structure of NPP2 was recently determined by Hausmann et al.
(2011) and Nishimasu et al. (2011). It revealed a rigid structure
with a deep hydrophobic lysophospholipid-binding pocket and
a nearby open tunnel, which might serve as an LPA product-
release channel. The SMB domains were found to contact the
catalytic domain where they contribute to the formation of the
tunnel (Hausmann et al., 2011; Nishimasu et al., 2011). In addi-
tion the SMB domains mediate the binding of NPP2 to cell
surface integrins, providing a mechanism for localized LPA pro-
duction and signaling (Fulkerson et al., 2011; Hausmann et al.,
2011; Moolenaar and Perrakis, 2011).
In NPP1, however, the SMB domains have been implicated in
homodimerization (Bellacchio, 2012; Gijsbers et al., 2003b).
Furthermore, NPP1 contains a small N-terminal intracellular
region and a transmembrane domain, accounting for its localiza-
tion in the plasmamembrane (Bello et al., 2001; Vaingankar et al.,
2004). In contrast the N-terminal hydrophobic region of NPP2
functions as a signal peptide (Jansen et al., 2005; Koike et al.,
2006), explaining why NPP2 is a secreted protein. Intriguingly,
a significant fraction of NPP1 is detected as a soluble monomer
in the blood and other body fluids (Belli et al., 1993), but it
remains unknownwhether soluble NPP1 originates from ectodo-
main shedding or intracellular processing.
To answer key questions concerning the structure and func-
tion of NPP1, we set out to determine its crystal structure and,
furthermore, to elucidate the mechanisms of NPP1 dimerization
and secretion. Here, we explain the formation of membrane-
bound NPP1 homodimers and soluble monomers via intramem-Structure 20, 1948–19brane disulfide bonding and intracellular processing, respec-
tively, and we present a crystal structure of secreted NPP1.
The structure features a nucleotide-binding groove, but it lacks
the hydrophobic pocket and the tunnel that characterize NPP2.
We find that, unexpectedly, the SMB domains are highly flexible
and do not contact the PDE domain. Furthermore, the structure
allows us to predict the structural impact of pathogenic muta-
tions in ENPP1. Our results provide insights into what makes
NPP1 a unique nucleotide pyrophosphatase, and they help to59, November 7, 2012 ª2012 Elsevier Ltd All rights reserved 1949
Figure 2. NPP1 Dimerization Is Mediated by
Three Transmembrane Cysteines
(A) The NPP1 transmembrane domain contains
three Cys residues (bold) that are phylogeneti-
cally conserved. Mm, Mus musculus; Hs, Homo
sapiens; Bt, Bos taurus; Pa, Papio anubis; Dn,
Dasypus novemcinctus; Hg, Heterocephalus
glaber; La, Loxodonta africana.
(B) The three transmembrane Cys residues were
mutated to Ala, individually or in combination, and
their expression as monomers or dimers was
analyzed by immunoblotting under nonreducing
conditions, using anti-Myc antibodies. In each
condition the same amount of NPP1 was loaded,
as quantified by PDE activity assays. The per-
centage of dimeric NPP1 (mean ± SEM; n = 3
independent experiments) compared to the total
signal is indicated below the blot.
(C) NPP1-EGFP was coexpressed with Myc-
tagged NPP1-WT, NPP1-C75A/C83A, or NPP1-
C67A/C75A/C83A. The cell lysates (600mgprotein)
were incubated with anti-EGFP beads or anti-Myc
antibodies, and the immunoprecipitates were
analyzed by immunoblotting with both anti-Myc
and anti-EGFP antibodies. Clear coimmunopreci-
pitation signals were only detected for NPP1-WT,
indicating that the formation of heterodimers of the
Cys mutants and NPP1-WT is impaired.
Structure
Structure of NPP1clarify how disease-causing mutations affect the structural
integrity of NPP1.
RESULTS
Secreted and Membrane-Bound Forms of NPP1
To explore the determinants of NPP1 secretion and dimerization,
we expressed mouse NPP1 with an N-terminal HA tag and
a C-terminal Myc tag in HEK293T cells and examined cell lysates
under nonreducing conditions by immunoblotting. We identified
dimeric and monomeric NPP1 bands that could be visualized
with anti-HA and anti-Myc antibodies (Figure 1B). In addition
the cell lysates contained an NPP1 monomer that was detected
by anti-Myc but not anti-HA antibodies, indicative of N-terminal
truncation. This processed monomer was the major NPP1
species in the culture medium and thus represents the secreted
form of NPP1.
N-terminal sequencing of secreted NPP1, purified using an
anti-Myc affinity column, showed that its first residue was
Lys85. This secreted form of NPP1 could be generated by intra-
cellular processing or ectodomain shedding from the plasma
membrane. To distinguish between these possibilities, we
generated fusion proteins with both an N-terminal EYFC tag
and a C-terminal ECFP tag. These fusions were made with
wild-type (WT) NPP1 and the Ser74 to Ala (S74A) mutant, which
was secreted more efficiently (Figure 1C). Uncleaved NPP1
mainly accumulated in the Golgi apparatus and at the plasma
membrane, in accordance with NPP1 being an integral mem-
brane protein (Figure 1D). However, a fraction of NPP1 was
processed intracellularly. Intracellular accumulation of cleaved
NPP1 was much more pronounced for the S74A mutant, as
expected from its more efficient secretion. Collectively, these
data indicate that the soluble pool of NPP1 is generated by the1950 Structure 20, 1948–1959, November 7, 2012 ª2012 Elsevier Ltdcleavage and removal of an N-terminal region that includes
the transmembrane domain. Consistent with this finding, the
Signal-P program predicts the NPP1 transmembrane domain
to be part of a weak signal sequence with a signal peptidase
cleavage site between Ala84 and Lys85, in agreement with the
N-terminal sequencing results.
Because secreted NPP1 is amonomer, the disulfide-mediated
homodimerization of membrane-bound NPP1 is likely to be
mediated by cysteines in the transmembrane domain rather
than those in the SMB domains. NPP1 contains three conserved
cysteines in its transmembrane region (Figure 2A). Mutation of
each of these cysteines individually did not affect dimer forma-
tion under nonreducing SDS-PAGE conditions. However, com-
bined mutagenesis of the cysteines largely abolished dimer
formation, strongly suggesting that NPP1 dimerization involves
multiple transmembrane disulfide bonds (Figure 2B). This was
validated by showing that NPP1-EGFP and NPP1-Myc coimmu-
noprecipitated from HEK293 cell lysates, whereas little or no
interaction was seen with the double or triple Cys mutants (Fig-
ure 2C). From these results we conclude that NPP1 dimerization
is mediated by disulfide bridges in the transmembrane domain.
The Crystal Structure of NPP1
To obtain a detailed understanding of the catalytic mechanism
and substrate-specifying determinants of NPP1, we set out to
determine the structure of NPP1 by X-ray crystallography. We
used the N-acetyl-glucosaminyltransferase-deficient HEK293S
GnTI cell line (Reeves et al., 2002) to stably express the ectodo-
main of mouse NPP1 (residues 87–906) fused to the signal
peptide of rat NPP2 (residues 1–33). Secreted NPP1 was affinity
purified and crystallized. The structure was determined by
molecular replacement, using the PDE and NUC domains of
NPP2 as a search model (Hausmann et al., 2011; NishimasuAll rights reserved
Figure 3. The Structure of NPP1
(A) Cartoon representation of the asymmetric unit that contains two molecules
of secreted NPP1, showing the catalytic PDE domain (green) flanked N
terminally by the two SMB domains (magenta and purple) and linked to the
NUC domain (blue) by a long linker wrapped around the NUC and referred to
as ‘‘lasso loop’’ (orange). Molecule B is shown in faded colors.
(B) The zinc ions in the catalytic site as well as the calcium ion bound by the EF
hand-like motif are represented by blue-gray and green spheres, respectively.
The disulfide bonds are shown as sticks with the sulfur atoms in yellow. The
N-linked glycans are shown as sticks with carbon atoms in white. Only the
SMB domains of molecule A could be built in the electron density maps, and
they crossover to molecule B.
(C) Cartoon representation of NPP2, in a similar orientation asmolecule A in (A),
emphasizing the different orientation of the SMB domains and the tight
interaction with the PDE domain.
Table 1. Crystallographic Data Collection and Refinement
Statistics
Data Collection
Space group P212121
Cell dimensions
a, b, c (A˚) 103.4, 105.4, 245.3
Resolution (A˚) 50.0–3.00 (3.16–3.00)
Rmerge 0.051 (0.640)
I/sI 17.1 (2.1)
Completeness (%) 99.8 (99.8)
Redundancy 3.7 (3.8)
Correlation (50) 0.99 (0.77)
Refinement
Resolution (A˚) 48.5–3.0
No. of reflections 51,597
Rwork/Rfree 0.200/0.233
No. of atoms
Protein 12,573
Ligand/ion 10/6
Carbohydrate 245
Water –
B factors (A˚2)
Wilson 110
Average of atoms 116
RMS
Bond (A˚) RMS/RMS-Z 0.007/0.347
Angles () RMS/RMS-Z 1.267/0.551
Validation (MolProbity)
Ramachandran favored 95.6%
Ramachandran outliers 0.06%
MolProbity score 100%
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Structure of NPP1et al., 2011), which showed that the asymmetric unit of the crystal
contained two NPP1 monomers. After refinement, the SMB
domains of the first NPP1 monomer (molecule A) could be
added, but the SMB domains of the second NPP1 monomer
(molecule B) were not visible in the electron density map,
presumably due to disordering in the solvent (Figure 3A). The
structure was refined at 3.0 A˚ resolution by BUSTER (Smart
et al., 2012) and REFMAC (Murshudov et al., 2011) to a free R
factor of 23%. Of note, MolProbity ranks it higher than any other
crystal structure determined in that resolution (100th percentile;
see Table 1 for crystallographic parameters and methods).Structure 20, 1948–19The NPP1 structure shows that the PDE and NUC domains of
NPP1 are tightly associated together and that the PDE-NUC
interface has similar characteristics as in NPP2 (Figures 3B
and 3C). The interface area is about 1,540 A˚2 and contains 14
hydrogen bonds and five salt bridges, making it marginally
more extensive than in NPP2 (1,280 A˚2, 7 hydrogen bonds and
nine salt bridges). A striking difference is observed in the orienta-
tion of the tandem SMB domains. The SMB domains in NPP1
(molecule A) do not contact the PDE domain, in contrast to
what is observed in NPP2. In NPP2 the SMB domains form
extended interfaces with the PDE domain, with a nearly identical
position in three different crystal packing configurations, and
form an essential part of the putative product-release tunnel
close to the active site (Hausmann et al., 2011; Nishimasu
et al., 2011). In NPP1, however, the SMB domains extend in
the opposite direction from the catalytic domain in onemonomer
and disappear in the bulk solvent in the second monomer
(Figure 3A).
The twomolecules in the asymmetric unit of the NPP1 crystals
show several interactions (Figure 3A). The SMB domains of
molecule A are in direct contact with the PDE domain of mole-
cule B, forming a weak dimer between both NPP1 molecules59, November 7, 2012 ª2012 Elsevier Ltd All rights reserved 1951
Figure 4. Comparison of the PDE-NUC
Domain Interfaces in NPP1 and NPP2
(A) Mutation of Cys413 and Cys805 abolishes
the enzymatic activity of NPP2, but this is not
observed after mutation of the corresponding
residues of NPP1.
(B) Cys413 and Cys805 link the NUC and the PDE
domains.
(C) The Asn residues of the eight predicted
glycosylation consensus motifs in NPP1 were
mutated to Ala. The bar diagram shows the
nucleotide phosphodiesterase activities (PDEase)
of all the tested variants, expressed as mean ±
SEM (n = 3). Only N567, which corresponds to the
essential glycosylation site N524 in NPP2, is
essential for NPP1 activity.
(D) The essential glycan, shown as a sphere model
with carbons in pink, is located between the PDE
and NUC domains shown as solid surfaces
(colored as in Figure 3).
(E) Mutation of the very C-terminal ‘‘LKT’’ motif
severely compromises the enzymatic activity of
NPP2, but only partially reduces NPP1 activity.
(F) Stick model showing how Lys896 forms a salt
bridge with Glu874 and a hydrogen bond with the
carbonyl oxygen of Phe881.
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Structure of NPP1with an interface of about 650 A˚2, as calculated by PISA (Krissinel
and Henrick, 2007). The PDE and NUC domains of the twomole-
cules are also in contact and have an interface area of about
450 A˚2. PISA ranks the resulting dimer as probably unstable in
solution, consistent with secreted NPP1 being monomeric.
However, transmembrane-mediated dimerization may promote
additional noncovalent contacts between adjacent NPP1 ecto-
domains, similar to what we observe in this particular crystal
packing (Figure 3A).
The linker region or ‘‘lasso loop’’ that connects the PDE and
NUC domains in NPP2 is conserved in NPP1, as is the disulfide
bridge between both domains. Mutation of the respective cyste-
ines in NPP2 abolishes catalytic activity, whereasmutation of the
corresponding cysteines in NPP1 has no effect (Figure 4A),
although the disulfide bridge is similar in both proteins
(Figure 4B).
Site-directed mutagenesis showed that N567 is the only pre-
dicted glycosylation site that is essential for activity (Figure 4C).
The saccharide at N567 is well visible (Figure 4D) and interfaces
with both the PDE and the NUC domain (area of about 240 A˚2),
similar to the essential N524 glycosylation in NPP2 (about
320 A˚2). Of the other five glycosylation sites identified by mobility
shifts in SDS-PAGE, residues N323, N459, and N624 are clearly
glycosylated. N267 is only glycosylated in one of the monomers,
whereas N583 does not show an ordered glycan, but this does
not argue against its glycosylation.1952 Structure 20, 1948–1959, November 7, 2012 ª2012 Elsevier Ltd All rights reservedAnother critical feature of the PDE-
NUC domain interface is the C-terminal
helix, starting at residue 887. As in
NPP2, this helix maps to the PDE-NUC
interface with an area of about 650 A˚2.
As shown in Figure 4E, Lys896 in the
very C-terminal ‘‘LKT’’ motif of NPP1 isless critical for catalytic activity than is the corresponding lysine
in NPP2 (Jansen et al., 2009). In NPP1 this helix forms a salt
bridge with Glu874 and a hydrogen bond with the carbonyl
oxygen of Phe881 (Figure 4F).
It thus appears that, whereas in NPP2 any disruption of the
PDE-NUC interface is detrimental to catalytic activity, similar
interventions in NPP1 are well tolerated (except for removal of
the essential N-linked glycosylation). These observations point
to an important difference between NPP1 and NPP2.
Substrate Binding and Catalysis
The bimetal catalytic site of NPP1 appears to be very similar to
that of NPP2 and the homologous nucleotide pyrophosphatase
from the bacterial pathogen Xanthomonas axonopodis (Xa-
PDE) (Zalatan et al., 2006) (Figure 5). Each zinc ion is coordinated
by three residues (Asp200, Asp405, and His406 for Zn1; Asp
358, His362, and His517 for Zn2), and mutation of any of these
residues abolishes catalytic activity (Gijsbers et al., 2001). The
active site Thr238 is also in a similar configuration as in NPP2
and Xa-PDA. The same applies to Asn259, which is character-
istic for pyrophosphatase/phosphodiesterases, whereas it is
an arginine in phosphatases. Similar to NPP2 (Hausmann et al.,
2011), a phosphate ion is bound to the NPP1 active site. These
similarities suggest a conserved two-step in-line displacement
mechanism for substrate catalysis by NPP1, similar to other
phosphodiesterases and alkaline phosphatase family members.
Figure 5. Comparison of the Catalytic Sites of NPP1, NPP2, and Bacterial Xa-PDE
Stick representation of the metal-binding residues, the catalytic site Thr, and the phosphodiesterase-specific Asn in the active site of NPP1 (A), NPP2 (B), and
Xa-PDE (C). Also shown is a pyrophosphatase/phosphodiesterase-specific Asn. The phosphate ions bound in NPP1 and NPP2 have been omitted for clarity.
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Structure of NPP1NPP1, NPP2, and Xa-PDE (Figure 6) all bind and hydrolyze
nucleotide substrates in vitro, although NPP2 is less effective
than NPP1 (Cimpean et al., 2004; Gijsbers et al., 2003b). Super-
posing the structure of NPP1 to that of Xa-PDE in complex with
AMP clearly demonstrates why AMP (and presumably other
nucleotides) binds well to NPP1 (Figures 7A and 7B). The
residues defining the Xa-PDE nucleotide-binding pocket
(Phe91, Leu123, Ser155, Glu160, Tyr174, and Tyr205) (Zalatan
et al., 2006) are conserved in NPP1 (Phe239, Leu272, Asp
308, Tyr322, Tyr353), with the exception of Ser155, which is
Phe303 in NPP1. However, this should not affect nucleotide
binding. Of more interest are Asp210 and Glu211 in Xa-PDE,
which contact the O3 and O2 hydroxyls of the ribose. In NPP1
the equivalent Asp358 is conserved, but the adjacent residue
is Ser359, suggesting that NPP1 has a somewhat reduced
affinity for AMP. Of interest is also Lys176 in Xa-PDE, which
forms a salt bridge to the electronegative N3 of the adenosine
base. The equivalent residue in NPP1 (Ser325) would be unable
to fulfill that role. However, Lys273 (equivalent to Ser124 in Xa-
PDE) compensates for that loss, coming from a different loop
to approximately the same position. Thus, the Nz atom is struc-
turally conserved in both NPP1 and Xa-PDE, albeit provided by
different residues.
In contrast to NPP2, NPP1 fails to hydrolyze lysophospholi-
pids (Gijsbers et al., 2003a) and is insensitive to potent NPP2
inhibitors such as HA130 and HA155 (Albers et al., 2010; Haus-
mann et al., 2011). It has been argued that an 18-residue deletion
in NPP2 facilitates the formation of a deep hydrophobic pocket
(Hausmann et al., 2011; Nishimasu et al., 2011). As expected,
NPP1 lacks this hydrophobic pocket. The 18-residue sequence
in NPP1 wraps around the PDE domain, filling up the hydro-
phobic pocket as it rejoins the PDE fold from the opposite side
(Figure 6A), similar to the situation in Xa-PDE (Figure 6B). Struc-
tural superposition tomouse NPP2 bound to LPA(14:0) and to rat
NPP2 bound to HA155 confirms that neither LPA nor HA155 can
be accommodated in the catalytic site of NPP1 because this
would result in severe clashes with the additional residues in
NPP1 (Figures 7C–7H). In NPP2 the SMB domains participate
in the formation of the putative product-release tunnel (Haus-
mann et al., 2011; Moolenaar and Perrakis, 2011; Nishimasu
et al., 2011, 2012). Obviously, this tunnel cannot be formed inStructure 20, 1948–19NPP1 because of the entirely different conformation of the
SMB domains (Figures 7E and 7F).
It is of note that the catalytic domain of NPP1 lacks 6 residues
in the region corresponding to residues 456–471 in NPP2. Resi-
dues 459–467 of NPP2 are disordered, whereas the correspond-
ing residues of NPP1 and Xa-PDE are well ordered (Figures 6A
and 6B). These residues are almost directly opposite to the
18-residue-deleted region in NPP2 and in close proximity to
the phosphate groups of the nucleotide substrates. This well-
ordered loop might be important for substrate binding, shielding
the phosphate from the solvent upon binding, and explain
why NPP1 is more efficient in hydrolyzing nucleotides than
NPP2/ATX.
Taken together, these results provide a structural basis for the
distinct substrate preferences of NPP1 and NPP2. In particular
they highlight why NPP1 is a specialized nucleotide pyrophos-
phatase unable to hydrolyze lipid substrates.
Structural Impact of Disease-Associated Mutations
Established or presumed loss-of-function mutations in NPP1 or
decreased local expression levels of NPP1 are closely associ-
ated with calcification disorders (see Introduction). Virtually all
disease-associated mutations in NPP1 map to the PDE and
NUC domains, but they do not affect the Thr256 nucleophile,
the metal binding, or glycosylation sites (Table 2). To understand
how the documented mutations may impact on NPP1 structure,
we analyzed select mutations interactively for their structural
context and calculated if they are on the protein surface or buried
in the interior using PISA (Krissinel and Henrick, 2007). We
also performed a computational mutagenesis experiment, using
FoldX (Schymkowitz et al., 2005), to estimate the effect on
protein stability. According to our analysis, many mutations
affect protein stability, and a few may promote protein aggrega-
tion, whereas yet a few others have no obvious structural effect
(Table 2). One mutation, Y317F, identified in patients with GACI
(Ruf et al., 2005), will directly affect substrate binding and catal-
ysis because the implicated tyrosine (Tyr353 in mouse NPP1) is
involved in defining the shape of the nucleotide-binding groove.
Mutation Y901S, identified in patients with hypophosphatemia,
results in complete loss of activity, whereas NPP1(Y910S) shows
normal expression at the plasma membrane (Levy-Litan et al.,59, November 7, 2012 ª2012 Elsevier Ltd All rights reserved 1953
Figure 6. Substrate-Specifying Determinants of NPP1, NPP2, and Xa-PDE
Cartoon representations of the PDE domain of NPP1 (A), Xa (B), and NPP2 (C). An 18-residue loop (ruby) blocks the binding of lysophospholipids to the catalytic
sites of NPP1 and Xa-PDE. An ordered loop (orange) in NPP1 and Xa-PDE is suggested to interact with the b or g phosphates of nucleotide substrates. A loop in
NPP2, which is partially disordered (residues 456–471; orange), is 6 residues shorter in NPP1 (residues 505–514; orange) and well ordered in both NPP1 and
Xa-PDE. This ‘‘phosphate-cap’’ loop might be involved in substrate binding, shielding the phosphates from the solvent.
Structure
Structure of NPP12010). Our analysis shows that the Y901S mutation disrupts two
hydrogen bonds with Thr836 and Thr853, respectively (Table 2),
highlighting the importance of a well-ordered NUC domain for
supporting catalytic activity.
DISCUSSION
Together with NPP2 (ATX), NPP1 is the best-characterized NPP
family member. Both enzymes are of vital importance in health
and disease, yet there are still many important questions that
remain to be answered. Here, we solve the structure of NPP1
and elucidate the mechanism of NPP1 dimerization and secre-
tion. Moreover, the structure allows us to predict the structural
consequences of disease-causing mutations in ENPP1. After
completion of our studies, a preliminary crystallographic analysis
of mouse NPP1 was reported by Kato et al. (2012).
NPP1 is expressed both as a disulfide-bonded homodimer in
the plasma membrane and as a soluble, N-terminally cleaved
monomer. Previous studies suggested that NPP1 dimerization
involves the Cys-rich SMB domains (Bellacchio, 2012; Gijsbers
et al., 2003b). However, our preliminary results indicate that
cysteine mutations in the SMB domains interfere with NPP1
trafficking to the plasma membrane, hinting at improper post-
translational processing rather than impaired dimerization
(unpublished data). Here, we show that NPP1 dimerizes via three
intramembrane disulphide bonds, not involving the SMB
domains. We envision that NPP1 dimerization occurs through
a zipper-like mechanism initiated by pairing of the transmem-
brane cysteines. Additional interactions between the ectodo-
mains may contribute to stable NPP1 dimer formation in the
plasma membrane. Bringing the two molecules together may
subsequently facilitate further ectodomain interactions, possibly
similar to those observed in the crystallographic dimer (Fig-
ure 3A). It is not uncommon for transmembrane proteins to1954 Structure 20, 1948–1959, November 7, 2012 ª2012 Elsevier Ltdform homodimers via intramembrane disulfide bridges. For
example, glycosyltransferases (Sousa et al., 2003), synaptobre-
vin (Roy et al., 2004), and some cell surface receptors (Berthouze
et al., 2007) form covalent dimers through transmembrane
cysteines. Stable dimer formation of membrane-bound enzymes
or receptors may serve to enhance catalytic efficiency or signal
strength, respectively. In this respect it is noteworthy that
NPP1 can stimulate osteoblast differentiation and gene expres-
sion via a signaling mechanism that is independent of NPP1
enzymatic activity (Nam et al., 2011). It will be interesting to
examine whether this putative signaling function of NPP1
depends on its homodimerization and/or sequences in its
N-terminal cytosolic tail.
Nearly half of the ectopically expressed NPP1 is found in the
medium as an N-terminally cleaved monomer, whereas NPP1
is also detected in the circulation. We show here that secreted
NPP1 is generated by intracellular proteolysis rather than by ec-
todomain shedding, in accordance with a previous study
showing that soluble NPP1 is not derived from the membrane-
bound pool (Belli et al., 1993). In silico analysis suggests that
the transmembrane region may function as a weak signal
sequence, implying that soluble NPP1 is secreted via the clas-
sical secretory pathway.
When compared to NPP2, NPP1 has a number of unique
structural features. First, the catalytic domain of NPP1 lacks
both the hydrophobic pocket and the tunnel found in NPP2,
accounting for the distinct substrate specificities of NPP1 and
NPP2. The higher efficiency of NPP1 compared to NPP2 in
hydrolyzing nucleotide substrates might be due to a ‘‘phos-
phate-capture loop’’ that is well ordered in NPP1, whereas the
corresponding region in NPP2 is four residues shorter and disor-
dered in all reported crystal structures.
The PDE-NUC interface is conserved in NPP1 and NPP2,
yet functionally distinct properties are evident. In particular,All rights reserved
Figure 7. Substrate-Binding Grooves of
NPP1, NPP2, and Xa-PDE
(A and B) AMP was modeled onto the NPP1 active
site surface by superposition of the Xa-PDE
structure in complex with AMP (PDB 2GSU) to the
NPP1 structure.
(C–H) The same procedure was performed to
simulate the binding of LPA(14:0) (C–F) and the
small molecule inhibitor HA155 (G and H), using
superposition of the NPP2 structure in complex
with LPA(14:0) and HA155 (PDB 3NKN and 2XRG,
respectively). The surface plots emphasize how
the 18-residue loop (ruby) in NPP1 and Xa-PDE
fills in the hydrophobic pocket extending from the
active site in NPP2 (D) and how it cooperates with
the SMB domains (gray) to form the ‘‘product-
release’’ tunnel (F); both features are missing in
NPP1 (C and E).
Structure
Structure of NPP1disruption of the disulfide bridge linking the PDE and NUC
domains or mutation of the very C-terminal LKT motif renders
NPP2 inactive, but these disruptions have little or no effect on
NPP1 activity. Thus, whereas the NPP2 NUC domain may serve
to stabilize and maintain the conformation of the PDE domain,
particularly its thermodynamically unstable hydrophobic lipid-
binding pocket, the strength of the NUC-PDE interaction in
NPP1 appears to be less critical for maintaining the active site
architecture.
A peculiar feature of NPP1–NPP3, when compared to NPP4–
NPP7, is the presence of two SMB domains arranged in tandem
(Stefan et al., 2005). In NPP2 these domains tightly interact with
the PDE domain to form a putative product-release tunnel;
furthermore, they mediate the binding of secreted NPP2 to acti-Structure 20, 1948–1959, November 7, 2012 ªvated integrins (Fulkerson et al., 2011;
Hausmann et al., 2011). In marked con-
trast the SMB domains in the secreted
form of NPP1 are highly flexible and
do not contact the PDE domain. As
a consequence, NPP1 lacks the putative
product-release tunnel. Although the
function of the SMB domains of NPP1
remains as yet unclear, one interesting
possibility is that they target secreted
NPP1 to cell surface integrins, in amanner
similar to that observed in NPP2 (Fulker-
son et al., 2011; Hausmann et al., 2011;
Moolenaar and Perrakis, 2011).
Some 40 disease-associated muta-
tions in ENPP1 have been identified to
date (Lorenz-Depiereux et al., 2010;
Nitschke et al., 2012; Ruf et al., 2005;
Rutsch et al., 2003, 2008), particularly in
GACI, a life-threatening disease, and
in patients with hypophosphatemia. A
number of these mutations lead to loss
of enzymatic activity in reconstituted cell
systems, as summarized in Table 2.
Many of these mutations affect protein
stability, a few may promote proteinaggregation, and yet a few others have no obvious structural
effect (Table 2). Yet, to our knowledge, it remains to be examined
to what extent the stability-affecting missense mutations in
NPP1 affect function. In general, loss of structure stability does
not necessarily lead to loss of enzymatic activity, but it could
equally well lead to reduced protein abundance due to misfold-
ing during biosynthesis (e.g., Shi et al., 2012; Yue et al., 2005). On
the other hand, an increase in NPP1 activity may also contribute
to pathologies, notably osteoarthritis (Johnson et al., 2001; Sun
et al., 2010) and calcification of the aortic valves (Coˆte´ et al.,
2012), suggesting that local inhibition of NPP1 activity is a valu-
able therapeutic strategy in these cases.
In conclusion the structure of NPP1 complements and extends
the huge amount of biological and functional data on NPP1. Our2012 Elsevier Ltd All rights reserved 1955
Table 2. Disease-Associated Mutations in NPP1 and Their Predicted Structural Impact
Reference Human Mutant Mouse Residue ASA (A˚2) DDG (s) kcal mol1 Remarks/Structural Effect
SMB1 Domain
1 C126Ra C108 0 15.0 (0.5) Disulfide disruption: destabilization, aggregation, misfolding
PDE Domain
2 S216E S198 0 5.2 (0.4) Buried: mildly destabilizing mutation
2 G242E G224 0 29.1 (0.4) Buried: strongly destabilizing mutation
3 P250L P232 0 7.5 (0.1) Buried: destabilizing mutation
4 G266V G248 54 23.0 (0.1) Solvent exposed: however, mutation to Val not tolerated
3 P305T P287 0 4.7 (0.1) Buried: mildly destabilizing mutation
2 R349K R331 1 3.2 (0.3) Buried: mildly destabilizing mutation, but near active site
3 Y371F Y353 19 0.9 (0.0) Tyr-OH involved in nucleotide binding
1 R456Qa R438 1 2.9 (0.8) Buried: mildly destabilizing mutation, but near active site
2 Y471C Y453 17 2.4 (0.0) Solvent exposed: disulfide-mediated aggregation
2 H500P H482 16 7.0 (0.1) Mildly destabilizing: proline may disrupt local structure
2 S504R S486 21 9.7 (0.1) Destabilizing mutation
2 Y513C Y495 16 3.5 (0.1) Solvent exposed: disulfide-mediated aggregation
5 D538H D520 5 8.9 (1.4) Destabilizing mutation
2 Y570C Y552 0 5.0 (0.1) Solvent exposed: disulfide-mediated aggregation
1 L579Fa L561 9 5.8 (0.0) Near the surface but facing inside: destabilizing mutation
5 G586R G568 12 14.3 (0.2) Strongly destabilizing mutation
NUC Domain
2 Y659C Y640 10 0.1 (3.6) Solvent exposed: disulfide-mediated aggregation
1 E668K Q649 145 0.8 (0.1) Solvent exposed: little effect on structure
1 C726Ra C707 0 15.0 (0.3) Disulfide disruption: destabilization, aggregation, misfolding
1 R774Ca H755 116 n/a Solvent exposed: disulfide-mediated aggregation
2 H777R H758 11 1.8 (0.1) Mildly destabilizing mutation
1 N792Sa N773 4 0.9 (0.1) Buried: smaller residue well tolerated
3 D804H D785 41 1.3 (0.3) Solvent exposed: minimal effect on structure
3 R821P R802 119 3.4 (0.5) Solvent exposed: mutation to Pro leads to destabilization
3 R888W R869 3 7.8 (2.1) Buried: mutation disrupts two hydrogen bonds
6 Y901Sa Y882 7 5.3 (0.1) Buried: mutation disrupts two hydrogen bonds
See text for details. References: 1, Rutsch et al. (2003); 2, Rutsch et al. (2008); 3, Ruf et al. (2005); 4, Lorenz-Depiereux et al. (2010); 5, Nitschke et al.
(2012); 6, Levy-Litan et al. (2010). ASA, accessible surface area; DDG (s), change in free energy of folding upon mutation and associated SE of the
estimate from triplicate in silico experiments.
aLoss of catalytic activity, as measured in reconstituted cell systems.
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Structure of NPP1results open new perspectives to examine the function of the
tandem SMB domains, to explore the functional difference of
the integral membrane and secreted forms of NPP1, and to
help develop specific small molecule inhibitors or allosteric acti-
vators for the treatment of calcification disorders.
EXPERIMENTAL PROCEDURES
NPP1 Constructs
The construction of HA-NPP1-Myc was described previously (Jansen et al.,
2005). Site-directed mutagenesis of the transmembrane Cys residues, Ser74,
and the N-glycosylation consensus sites was performed using the Quik-
Change Site-Directed Mutagenesis Kit (Stratagene). To generate the
enhanced green and yellow fluorescent protein (EGFP and EYFP, respectively)
fusions of NPP1, the PCR-amplified cDNA of murine NPP1 (residues 35–905)
was subcloned into the pEGFP-N1 and pEYFP-C1 vector (Clontech), respec-
tively. The EYFP-NPP1-ECFP doubly tagged vector was constructed in a two-
step procedure. First, the stop codon in the EYFP-NPP1 vector was replaced
by a XhoI restriction site. Second, the ECFP encoding cDNA was PCR ampli-1956 Structure 20, 1948–1959, November 7, 2012 ª2012 Elsevier Ltdfied from the ECPF-C1 vector (Clontech), with sense and antisense primers
containing a XhoI and Cfr9I restriction site sequence, respectively, and in-
serted C terminally from the NPP1 cDNA into the modified EYFP-NPP1 vector
generated in the first step, after restriction of vector and insert with XhoI and
Cfr9I. Plasmids were used to transform the DH5a bacterial strain. Positive
colonies were identified by restriction digest or PCR analysis. All constructs
were verified by sequencing. The sequences of all primer sets used are avail-
able upon request.
Cell Culture
HEK293T cells were maintained at 37C under a humidified atmosphere
containing 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM), supple-
mented with 10% (v/v) heat-inactivated fetal bovine serum, glucose
(4.5 mg/ml), penicillin (100 U/ml), and streptomycin (100 mg/ml). Cells were
transiently transfected at 30%–40% confluency using JetPRIME (Polyscien-
ces). The cells were harvested 72 hr post-transfection, washed once in PBS,
and lysed in 50 mM Tris/HCl (pH 7.5), 0.5 mM phenylmethanesulphonyl fluo-
ride, 0.5 mM benzamidine, 150 mM NaCl, and 1% (v/v) Triton X-100. After
a 30 min extraction on ice and three freeze-thaw cycles, the cell lysates
were cleared by ultracentrifugation (45 min at 100,000 3 g). Aliquots of theAll rights reserved
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Structure of NPP1cell lysates were used for immunoblot analyses, immunoprecipitations, and/or
PDE activity assays. For immunoprecipitation, 600 mg of total cell lysate was
incubated overnight at 4C with either 20 ml of GFP-trap beads (ChromoTek)
or anti-Myc antibodies clone 9E10 (dilution 1:100). The anti-Myc-bound
proteins were subsequently incubated with 20 ml of Protein A TSK beads for
1 hr at 4C. Subsequently, both types of beads were washed three times
with Tris-buffered saline (TBS), supplemented with 0.25% NP40 and 0.1%
Triton X-100, before being resuspended in 20 ml sample buffer and processed
for immunoblotting.
Electrophoresis and Immunoblotting
Proteins were separated by SDS-PAGE using 4%–12% Bis-Tris gels (Invitro-
gen), transferred to polyvinylidene difluoride membranes (GE Healthcare),
and subjected to 60V for 2 hr in 192 mM glycine, 25 mM Tris, and 10% meth-
anol (pH 8.6). After blotting, nonspecific binding sites were blocked with 3%
BSA (Serva) or 5% milk in PBS with 0.1% Tween 20. Subsequently, the
membranes were incubated with anti-Myc (clone 9E10) monoclonal anti-
bodies, anti-HA (clone 12CA5), or anti-EGFP polyclonal antibodies (Santa
Cruz Biotechnology). After overnight incubation, proteins were visualized
using horseradish peroxidase goat anti-mouse or goat anti-rabbit IgG (Dako)
and enhanced chemiluminescence (PerkinElmer, Boston).
Nucleotide Phosphodiesterase Activity
Nucleotide phosphodiesterase activities of NPP1 and NPP2/ATX were deter-
mined from the release of p-nitrophenolate from p-nitrophenyl thymidine
50-monophosphate (pNP-TMP), as described (Jansen et al., 2009). Briefly,
the protein samples were incubated with 5 mM pNP-TMP, 5 mM CaCl2,
5 mM MgCl2, and 100 mM Tris/HCl (pH 9.0) in a total volume of 35 ml at
37C. The reaction was stopped by the addition of 100 ml of 6% (v/v) trichloro-
acetic acid. Subsequently, the mixture was neutralized with NaOH, and p-ni-
trophenolate was quantified colorimetrically at 405 nm.
Confocal Microscopy
HEK293T cells were seeded in 4-well chambers at 30,000 cells per well. Cells
were transfected using the JetPRIME transfection reagent with two-color
fluorescent NPP1 (EYFC-NPP1-ECFP). After 24 hr, the medium was removed,
and the cells were washed twice in PBS and fixed in 4% paraformaldehyde for
10min. Fluorescence wasmonitored directly using an LSM 510 Axiovert 100M
laser-scanning microscope (Zeiss). The noncleaved pool of NPP1 contains
both the EYFC (green) and ECFP (red) tags and can be visualized by detection
of the merged (yellow) color. The N-terminally cleaved pool only contains the
ECFP tag (red).
Expression and Purification of Soluble NPP1
A nontagged chimera of the signal peptide sequence of NPP2 and the
extracellular domain of mouse NPP1 was generated as described previously
(Jansen et al., 2005). Subsequently, this fusion construct was stably trans-
fected in HEK293S GnTI cells (Reeves et al., 2002) that were expanded
and maintained in serum-free medium (Ex-Cell 293; Invitrogen) in a
medium-cartridge fiber cell system (FiberCell Systems) with a 20 kDa
membrane cutoff. The culture medium was collected every day. For purifica-
tion of NPP1, 1 liter of medium was applied onto Blue Sepharose. After
washing with buffer A (20 mM Tris [pH 8.0], 150 mM NaCl, 0,01% NaN3),
retained NPP1 was eluted with buffer A supplemented with 850 mM NaCl.
The collected fractions were diluted with 20 mM Tris at pH 8.0 until the final
salt concentration was 50 mM, and applied to a Mono Q anion-exchange
column. Peak fractions were collected, concentrated, and remaining contam-
inants were removed by S200 Superdex gel filtration in 20 mM Tris (pH 8.0),
150 mM NaCl, and 0.01% NaN3.
The purified NPP1 protein was concentrated to 7 mg/ml by Vivaspin con-
centration columns and used to set up crystal drops consisting of 100 nl
protein solution with 100 nl 10% propanol, 0.1 M imidazole (pH 8.0), and 3%
1,4-dioxane. Crystals were vitrified in mother liquid supplemented with 30%
glycerol.
X-Ray Crystallography
X-ray diffraction data were collected at the Soleil beamline Proxima 1,
integrated by XDS (Kabsch, 2010) and scaled in SCALA (Evans, 2006). Molec-Structure 20, 1948–19ular replacement using the PDE and NUC domains of NPP2 in Phaser (McCoy
et al., 2007) resulted in a clear solution indicating two molecules in the asym-
metric unit. However, no solution for SMB1 and SMB2 could be obtained.
Automated model building in PHENIX (Adams et al., 2002) resulted in a good
model that was corrected and extended for the PDE and NUC domains in
Coot (Emsley et al., 2010). After several rounds of model building and refine-
ment in BUSTER (Smart et al., 2012), additional density for the SMB domains
of the first monomer was clear. The second SMB domain was placed by
FFFEAR (Cowtan and Main, 1998), using the refined 2mFo-DFc map from
the current state of refinement. The first SMB domain was placed manually
in Coot as a rigid body and thenmodified to fit the density. After several rounds
of additional refinement, using REFMAC (Murshudov et al., 2011) with
PDB_REDO-optimized settings (Joosten et al., 2012), model adjustment
guided by MolProbity (Chen et al., 2010), and pdb-care validation (Lutteke
and der Lieth, 2004), the free R factor was 23%. It also became clear that
the SMBdomains of the secondNPP1monomer are disordered and not visible
in the electron density map.
Structure Analysis
Interface analysis and solvent accessible area analysis were performed in
PISA (Krissinel and Henrick, 2007) using the standard web interface (http://
www.ebi.ac.uk/msd-srv/prot_int/). Protein stability calculations for the
disease-causing mutants and for the contribution of the NUC domain to
NPP1 and NPP2 stability were performed in FoldX (Schymkowitz et al.,
2005), using default parameters. SEs of the energy changes were obtained
by performing all computations in triplicate.ACCESSION NUMBERS
The atomic coordinates and structure factors of mouse NPP1 have been
deposited in the Protein Data Bank with accession code 4B56.
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